Back to Search Start Over

Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy

Authors :
Jonatan Kaszubski
Maciej Gagat
Alina Grzanka
Agata Wawrzyniak
Wiesława Niklińska
Magdalena Łapot
Agnieszka Żuryń
Source :
Molecules, Vol 29, Iss 22, p 5239 (2024)
Publication Year :
2024
Publisher :
MDPI AG, 2024.

Abstract

Melanoma occurs in various forms and body areas, not only in the cutis, but also in mucous membranes and the uvea. Rarer subtypes of that cancer differ in genomic aberrations, which cause their minor sensibility to regular cutaneous melanoma therapies. Therefore, it is essential to discover new strategies for treating rare forms of melanoma. In recent years, interest in applying CDK inhibitors (CDKIs) in cancer therapy has grown, as they are able to arrest the cell cycle and inhibit cell proliferation. Current studies highlight selective CDK4/6 inhibitors, like palbociclib or abemaciclib, as a very promising therapeutic option, since they were accepted by the FDA for advanced breast cancer treatment. However, cells of every subtype of melanoma do not react to CDKIs the same way, which is partly because of the genetic differences between them. Herein, we discuss the past and current research relevant to targeting various CDKs in mucosal, uveal and acral melanomas. We also briefly describe the issue of amelanotic and desmoplastic types of melanoma and the need to do more research to discover cell cycle dysregulations, which cause the growth of the mentioned forms of cancer.

Details

Language :
English
ISSN :
14203049
Volume :
29
Issue :
22
Database :
Directory of Open Access Journals
Journal :
Molecules
Publication Type :
Academic Journal
Accession number :
edsdoj.1412bbb49e584b14afa6fe943b266283
Document Type :
article
Full Text :
https://doi.org/10.3390/molecules29225239